Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 3/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3176956 | 0.80 | HTR1A (0.51) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL8301747 | 0.80 | HTR1A (0.51) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL2885978 | 0.79 | SIGMAR1 (0.54) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL8170356 | 0.75 | HTR1A (0.65) | HTR1ASIGMAR1 | |
| SCHEMBL8170360 | 0.75 | HTR1A (0.65) | HTR1ASIGMAR1 | |
| SCHEMBL652126 | 0.74 | HTR1A (0.47) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL22605206 | 0.74 | HTR1A (0.47) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL10078725 | 0.74 | HTR1A (0.47) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL652125 | 0.74 | HTR1A (0.47) | HTR1ASIGMAR1GBA1NPY1RHTT | |
| SCHEMBL9041117 | 0.73 | HRH3 (0.58) | HTR1ASIGMAR1ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | HTR1A 3690/4885SIGMAR1 517/4885GBA1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.